i
Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients
-
6 2021
-
-
Source: Am J Transplant. 21(6):2246-2253
[PDF-829.80 KB]
Details:
-
Alternative Title:Am J Transplant
-
Personal Author:
-
Description:Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years). We enrolled 50 patients of which 49 received at least one vaccine dose. Anti-glycoprotein E (gE) antibody levels (n = 43) increased significantly compared to baseline (median optical density [OD] 1.96; interquartile range [IQR]: 1.17-2.89) after the first (median OD 3.41, IQR 2.54-3.81, p < .0001) and second vaccine dose (median OD 3.63, IQR 3.39-3.86, p < .0001). gE-specific polyfunctional CD4+ T cell frequencies (n = 38) also increased from baseline (median 85 per 10| CD4+ T cells; IQR: 46-180) to the first (median 128 per 10| CD4+ T cells; IQR: 82-353; p = .023) and after the second dose (median 361 per 10| CD4+ T cells; IQR: 146-848; p < .0001). Tenderness (83.0%; 95%CI: 69.2-92.4%) and redness (31.9%; 95%CI: 19.1-47.1%) at injection site were common. One rejection episode within 3 weeks of vaccination was observed. This is the first study demonstrating that RZV was safe and elicited significant humoral and cell-mediated immunity in lung transplant recipients. RZV is a new option for the prevention of shingles in this population.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:33565711
-
Pubmed Central ID:PMC9169546
-
Document Type:
-
Funding:
-
Volume:21
-
Issue:6
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
